RBCC and n3D Pursue New Partnership Opportunities After Highly Successful 3D Bioprinting Exhibit at Biotech Showcase 2015
[ Back ]   [ More News ]   [ Home ]
RBCC and n3D Pursue New Partnership Opportunities After Highly Successful 3D Bioprinting Exhibit at Biotech Showcase 2015

MIRAMAR BEACH, Fla. — (BUSINESS WIRE) — February 5, 2015 — Rainbow Coral Corp. (OTCBB: RBCC) and Nano3D Biosciences (n3D) are lining up new 3D bioprinting opportunities and potential partnerships following a highly successful product exhibition last month at Biotech Showcase 2015 in San Francisco.

One of the world’s foremost investment and partnering conferences devoted to biotechnology, Biotech Showcase provided an idea platform to demonstrate the potential of the n3D Bio-Assembler to  investors and pharmaceutical executives from around the world. As industry leaders in the emerging field of three-dimensional cell culturing, RBCC and n3D have teamed up to deliver the world’s first commercially available  3D bioprinting system designed for high-throughput and high-content drug screening.

“Nano3D’s 3D bioprinting exhibit at Biotech Showcase put the Bio-Assembler on a pedestal under the bright lights,” said RBCC CEO Kimberly Palmer. “This device has nearly limitless applications for cellular research, and it turned quite a few heads in San Francisco.”

For months, RBCC and n3D have been focused on raising product awareness to further market and develop the Bio-Assembler and other 3D bioprinting technology around the globe. The device uses biocompatible magnetic nanoparticles to magnetically bioprint and levitate cells, allowing them to grow into 3D structures much faster and more simply than competing technologies.

“The interest that we’ve received from the Showcase attendees has broadened the scope and awareness of what the company is capable of,” Palmer said.

Through its biotech subsidiary, Rainbow Biosciences, RBCC markets and develops new medical and research technology innovations to compete alongside companies such as Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN). Rainbow Biosciences acquired an equity interest in n3D in 2012.

About Rainbow Biosciences

Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit  www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit  www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.


Rainbow Coral Corp.
Kimberly Palmer, 850-269-7230
President and CEO
Email Contact